HCA Healthcare (HCA) Earnings Date & Reports

Key Takeaways

• Revenue rose 8.7% year over year to $20.23 billion, in line with Wall Street expectations.
• Adjusted diluted earnings per share (EPS) came in at $7.59, narrowly ahead of the $7.57 consensus estimate.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) grew 4.6% to $4.03 billion.
• Same-facility admissions climbed 2.5%, while inpatient and outpatient surgeries declined 2.3% and 3.4%, respectively.
• Management lowered full-year 2026 EPS guidance to a range of $28.70 to $30.50, citing a sharp payer mix shift toward uninsured patients.

Earnings Context and Why It Matters

As the largest publicly traded hospital operator in the United States, HCA Healthcare is widely viewed as a barometer for the broader acute-care sector. Its quarterly results shed light on patient demand, staffing and supply costs, and the shifting mix of commercial, government, and uninsured payers. The second quarter of 2026 carried particular weight because it was the first full period to reflect the expiration of enhanced premium tax credits, which analysts feared would push more exchange enrollees into uninsured status. Those concerns proved justified, making this report a key test of how the company's scale and cost discipline can absorb a structurally less favorable payer environment.

Reported Results

For the second quarter ended June 30, 2026, HCA Healthcare reported revenue of $20.23 billion, up 8.7% from $18.61 billion in the prior-year period and in line with the Zacks consensus estimate. Adjusted diluted EPS of $7.59 edged past the $7.57 consensus, while GAAP (generally accepted accounting principles) net income attributable to the company rose 2.8% to $1.69 billion.

Adjusted EBITDA increased 4.6% to $4.03 billion. Volume trends were mixed: same-facility admissions grew 2.5%, equivalent admissions rose 2.7%, and emergency room visits increased 3.6%. However, same-facility inpatient surgeries declined 2.3% and outpatient surgeries fell 3.4%, reflecting softer elective procedure demand and the payer mix shift.

The most consequential development was guidance. Management narrowed full-year revenue guidance to $77.0 billion to $79.5 billion while lowering diluted EPS guidance to $28.70 to $30.50 (from $29.10 to $31.50) and Adjusted EBITDA guidance to $15.4 billion to $16.1 billion. The company attributed roughly $400 million of second-quarter pre-tax pressure to uninsured volume growth tied to exchange coverage losses and Medicaid redeterminations.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. By automating the screening process, the tool helps identify trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual research. For investors monitoring the hospital and healthcare services sector after an earnings report like this one, the AI Screener offers a structured way to surface actionable candidates quickly.

Market Reaction and Investor Sentiment

Investor reaction to the second quarter was decidedly cautious. HCA shares have lost roughly 19% since the start of 2026, a stark contrast to the broader market's gains, and the July 24 report reinforced the bearish case despite a top-line beat. Several sell-side analysts cut price targets immediately after the release, with Mizuho lowering its target to $475 from $525 and Morgan Stanley trimming its target to $380 from $425.

The central concern is not demand but payer mix. A larger-than-expected migration of former exchange enrollees into uninsured status is eroding revenue quality and pressuring margins, even as volumes remain resilient. Management's downward revision to profitability guidance signaled that this headwind is expected to persist through the second half of the year, keeping sentiment guarded heading into the next report.

Forward Outlook and Key Factors to Monitor

The biggest variable for the remainder of 2026 is the trajectory of the payer mix. HCA now expects the full-year exchange-related drag to reach $1.0 billion to $1.2 billion, partially offset by $300 million to $500 million in net benefits from Medicaid Supplemental Payment Programs. Investors should track whether uninsured volumes stabilize or continue rising, as that will directly influence margins and guidance.

Elective surgery trends also warrant attention. Inpatient and outpatient surgical volumes both declined, a reversal from prior quarters. Management has linked part of this softness to reduced exchange coverage and is investing in operating room capacity and physician alignment to recapture demand. A sustained recovery in elective procedures would support both revenue and EBITDA growth.

Finally, cost control and capital deployment remain important signals. The company is executing a financial resiliency program focused on digital transformation and operational efficiency, while also committing more than $7 billion to capacity expansion over the next three years. With strong cash generation funding dividends and share repurchases, how management balances reinvestment against shareholder returns will shape the investment narrative through the end of the fiscal year.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations